Top Tweets for #vRNA

Verona Pharma @VeronaPharma

about 1 year ago

$VRNA #VRNA BULL's EYE! 🎯

0

4

1

3

0

over 1 year ago

Today, we announced our financial results for the first quarter of 2025. We continue to see strong momentum in our launch. Join our investment community webcast at 9 a.m. ET / 2 p.m. BST: https://t.co/aZVHXCbs8w #VRNA

VeronaPharma's tweet photo. Today, we announced our financial results for the first quarter of 2025. We continue to see strong momentum in our launch.

Join our investment community webcast at 9 a.m. ET / 2 p.m. BST: https://t.co/aZVHXCbs8w

#VRNA https://t.co/EgUGaJW6Ce

0

5

0

262

VRSim, Inc. @VRSimInc

over 1 year ago

Our friends at CJPS are putting #VRNA EMS to work! Their juniors are getting a feel for patient care before they step into real life emergencies. Photo Credit: @bullard_tech

VRSimInc's tweet photo. Our friends at CJPS are putting #VRNA EMS to work! Their juniors are getting a feel for patient care before they step into real life emergencies.

Photo Credit: @bullard_tech https://t.co/J2VbFWenLm

0

2

0

16

Vanquish Adept @VanquishAdept

over 1 year ago

Top Stock Percentage Losses (03/14/25) Tesco PLC (#TSCDY) -7.77% XPeng Inc. (#XPEV) -6.39% Verona Pharma plc (#VRNA) -6.07% CK Hutchison Holdings Limited (#CKHUY) -5.25% Under Armour, Inc. (#UAA) -4.96% Li Auto Inc. (#LI) -4.39% Hesai Group (#HSAI) -3.70% Beam Therapeutics Inc. (#BEAM) -3.31% Avidity Biosciences, Inc. (#RNA) -3.17% The Gap, Inc. (#GAP) -3.03% Under Armour, Inc. (#UA) -2.96% Belite Bio, Inc (#BLTE) -2.94% Kering SA (#PPRUY) -2.92% NovoCure Limited (#NVCR) -2.84% Macy's, Inc. (#M) -2.81%

0

5

0

181

over 1 year ago

Even though the markets are showing a bounce only a handful of stocks are showing in our Early Morning Movers Bullish scan. Some examples, not recommendations are: #DWTX, #RYCEY, #GRRR, #BBVA, #SSRM, #VRNA. Let's see if they can hold up.

ConnieHillCS's tweet photo. Even though the markets are showing a bounce only a handful of stocks are showing in our Early Morning Movers Bullish scan. Some examples, not recommendations are: #DWTX, #RYCEY, #GRRR, #BBVA, #SSRM, #VRNA. Let's see if they can hold up. https://t.co/cL7iMYjrSV

1

7

1

0

467

Verona Pharma @VeronaPharma

over 1 year ago

Markets are off their lows and a few stocks are popping on the Early Morning Movers Bullish scan. Some examples, not recommendations are: #HIMS, #WBA, #LZ, #LTBR, #GRRR, #ADTN, #VRNA, #ACAD, #BROS. Let's see if these bounces hold.

ConnieHillCS's tweet photo. Markets are off their lows and a few stocks are popping on the Early Morning Movers Bullish scan. Some examples, not recommendations are: #HIMS, #WBA, #LZ, #LTBR, #GRRR, #ADTN, #VRNA, #ACAD, #BROS. Let's see if these bounces hold. https://t.co/RI1FJ9Swyw

0

9

0

1

625

over 1 year ago

We will announce our financial results for the full year of 2024 and host a conference call for the investment community on February 27th at 9:00 a.m. EST. #COPD #respiratorydisease #VRNA #earnings

VeronaPharma's tweet photo. We will announce our financial results for the full year of 2024 and host a conference call for the investment community on February 27th at 9:00 a.m. EST.

#COPD #respiratorydisease #VRNA #earnings https://t.co/9qcJ7iOMbB

0

6

1

0

373

over 1 year ago

Several up trending stocks from our Early Morning Movers scan are having some big breakouts. Some examples, not recommendations are: #AIFF, #UPST, #LTBR, #EH, #RDW, #HSAI, #XPEV, #RSI, #VRNA. Let's see if the moves hold up or fade.

ConnieHillCS's tweet photo. Several up trending stocks from our Early Morning Movers scan are having some big breakouts. Some examples, not recommendations are: #AIFF, #UPST, #LTBR, #EH, #RDW, #HSAI, #XPEV, #RSI, #VRNA. Let's see if the moves hold up or fade. https://t.co/K6j4WyBNj3

1

3

0

366

over 1 year ago

Several stocks are popping on the Early Morning Movers scan. Some examples, not recommendations are: #SSYS, #VIAV, #AR, #HSAI, #TEAM, #VRNA, #BKSY, #SFM, #EAT. Let's see if their gains hold today.

ConnieHillCS's tweet photo. Several stocks are popping on the Early Morning Movers scan. Some examples, not recommendations are: #SSYS, #VIAV, #AR, #HSAI, #TEAM, #VRNA, #BKSY, #SFM, #EAT. Let's see if their gains hold today. https://t.co/XXNMKSy1OX

0

4

0

345

over 1 year ago

$VRNA #VRNA Verona Pharma Analysis Ohtuvayre Product Launch and Market Performance Verona Pharma’s Ohtuvayre, offering an innovative solution for the treatment of COPD (Chronic Obstructive Pulmonary Disease), was approved in June 2024 and became the first new mechanism-based inhalation therapy in this field in the past 20 years. Following its launch, it generated $36 million in sales revenue in Q4 2024, exceeding expectations by 87%. Throughout 2024, 16,000 prescriptions were written, and the product was prescribed by 3,500 different physicians, demonstrating the market's interest in the product. Ohtuvayre is typically used in COPD patients where standard treatments (LABA-LAMA-ICS) are ineffective. While this limits its market, it performs strongly due to the high patient population and unmet needs. Financial Health and Company Status Verona Pharma has $336 million in cash reserves and $364 million in total assets, indicating the company has sufficient resources to operate at least until the end of 2026. The company’s total debt stands at $222 million ($120 million in loans and $102 million in revenue-based financing agreements). The company burns approximately $10.3 million in cash per month, confirming that it can sustain operations until the end of 2026 with its current cash position. The company’s strong financial position supports operational sustainability. However, Verona Pharma’s reliance solely on Ohtuvayre risks future revenue streams. Stock Performance Verona's market cap has risen from $600 million to $4.05 billion in a few months. Annual peak sales of Ohtuvayre are estimated to exceed $2 billion. However, Verona will need to achieve broader market penetration to reach this value. The stock’s short-term gains are largely attributed to the success of its product launch. However, much of its future growth may depend on a potential acquisition or merger. Risks Sales coming in below expectations. Competition from alternative treatments. Verona’s lack of a strong product portfolio beyond Ohtuvayre. Patent Status Ohtuvayre’s NCE (New Chemical Entity) protection period lasts until 2029. The core molecule patent expires in 2031. However, Verona has the potential to extend this period to 2035 with additional protections such as formulation and use patents. While this provides an important window of opportunity for Verona, the lack of a broader product portfolio poses a challenge for sustainable growth in the long term. Technical Analysis join for more 👉https://t.co/k01vMZXtTV

MarketMaestro1's tweet photo. $VRNA #VRNA
Verona Pharma Analysis

Ohtuvayre Product Launch and Market Performance
Verona Pharma’s Ohtuvayre, offering an innovative solution for the treatment of COPD (Chronic Obstructive Pulmonary Disease), was approved in June 2024 and became the first new mechanism-based inhalation therapy in this field in the past 20 years. Following its launch, it generated $36 million in sales revenue in Q4 2024, exceeding expectations by 87%. Throughout 2024, 16,000 prescriptions were written, and the product was prescribed by 3,500 different physicians, demonstrating the market's interest in the product.
Ohtuvayre is typically used in COPD patients where standard treatments (LABA-LAMA-ICS) are ineffective. While this limits its market, it performs strongly due to the high patient population and unmet needs.

Financial Health and Company Status

Verona Pharma has $336 million in cash reserves and $364 million in total assets, indicating the company has sufficient resources to operate at least until the end of 2026.

The company’s total debt stands at $222 million ($120 million in loans and $102 million in revenue-based financing agreements).
The company burns approximately $10.3 million in cash per month, confirming that it can sustain operations until the end of 2026 with its current cash position.
The company’s strong financial position supports operational sustainability. However, Verona Pharma’s reliance solely on Ohtuvayre risks future revenue streams.
Stock Performance

Verona's market cap has risen from $600 million to $4.05 billion in a few months.

Annual peak sales of Ohtuvayre are estimated to exceed $2 billion. However, Verona will need to achieve broader market penetration to reach this value.

The stock’s short-term gains are largely attributed to the success of its product launch. However, much of its future growth may depend on a potential acquisition or merger.

Risks
Sales coming in below expectations.
Competition from alternative treatments.

Verona’s lack of a strong product portfolio beyond Ohtuvayre.
Patent Status
Ohtuvayre’s NCE (New Chemical Entity) protection period lasts until 2029.
The core molecule patent expires in 2031. However, Verona has the potential to extend this period to 2035 with additional protections such as formulation and use patents.

While this provides an important window of opportunity for Verona, the lack of a broader product portfolio poses a challenge for sustainable growth in the long term.

Technical Analysis
join for more 👉https://t.co/k01vMZXtTV

0

8

0

1

2K

over 1 year ago

There are just a handful of stocks popping on our Early Morning Movers Bullish scan. Some examples, not recommendations are: #ITCI, #DJT, #BBIO, #ATEC, #CRGY, #VRNA, #WIX, #BDMD, #PCRX. Let's see if they can hold their gains.

ConnieHillCS's tweet photo. There are just a handful of stocks popping on our Early Morning Movers Bullish scan. Some examples, not recommendations are: #ITCI, #DJT, #BBIO, #ATEC, #CRGY, #VRNA, #WIX, #BDMD, #PCRX. Let's see if they can hold their gains. https://t.co/XqfmYxl5OP

1

9

0

441

Verona Pharma @VeronaPharma

over 1 year ago

The major indices are down but a few stocks are up in our Early Morning Movers Bullish scan. Some examples, not recommendations are: #CRNC, #NARI, #ENVX, #VRNA, #GDS, #VRNA, #ARQT, #AEHR, #AVXL. Let's see if these moves keep today.

ConnieHillCS's tweet photo. The major indices are down but a few stocks are up in our Early Morning Movers Bullish scan. Some examples, not recommendations are: #CRNC, #NARI, #ENVX, #VRNA, #GDS, #VRNA, #ARQT, #AEHR, #AVXL. Let's see if these moves keep today. https://t.co/WCCTbI6IuZ

0

5

0

510

over 1 year ago

Today, our management team reported preliminary fourth quarter and full year 2024 financial highlights, including an estimated $36 million and $42 million net sales of our FDA-approved product. Learn more: https://t.co/0KZi0PqmuY #VRNA #Earnings

0

9

0

787

over 1 year ago

$VRNA #VRNA BULL'S EYE! 🎯

0

4

0

Vanquish Adept @VanquishAdept

almost 2 years ago

Several Health Care sector stocks are dominating the results in our Early Morning Movers Bullish scan. Some examples, not recommendations are: #MAS, #BLCO, #TVTX, #SRRK, #SPRY, #CAPR, #VRNA, #OCUL, ILMN. Let's see if they keep their gains going into the close.

ConnieHillCS's tweet photo. Several Health Care sector stocks are dominating the results in our Early Morning Movers Bullish scan. Some examples, not recommendations are: #MAS, #BLCO, #TVTX, #SRRK, #SPRY, #CAPR, #VRNA, #OCUL, ILMN. Let's see if they keep their gains going into the close. https://t.co/LdMNbByklE

0

5

1

0

542

almost 2 years ago

Top Stock Percentage Gains (10/03/24) Futu Holdings Limited (#FUTU) +8.81% PBF Energy Inc. (#PBF) +7.98% MarketAxess Holdings Inc. (#MKTX) +7.46% Verona Pharma plc (#VRNA) +7.31% Vista Energy, S.A.B. de C.V. (#VIST) +6.85% HF Sinclair Corporation (#DINO) +6.35% Valero Energy Corporation (#VLO) +6.15% Banco BBVA Argentina S.A. (#BBAR) +6.12% Northern Oil and Gas, Inc. (#NOG) +5.97% DSV A/S (#DSDVY) +5.90% #Stocks #StockMarket

0

4

0

150

almost 2 years ago

We have some mixed markets but still a handful of stocks are showing on our Early Morning Movers scan. Some examples, not recommendations are: #VST, #WWW, #VRNA, #FUTU, #CEG, #TLN, #PLTR, #VKTX, #REPL. Let's see if they hold their momentum today.

ConnieHillCS's tweet photo. We have some mixed markets but still a handful of stocks are showing on our Early Morning Movers scan. Some examples, not recommendations are: #VST, #WWW, #VRNA, #FUTU, #CEG, #TLN, #PLTR, #VKTX, #REPL. Let's see if they hold their momentum today. https://t.co/n5eRiw4qkE

0

7

0

737